Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe coronavirus disease 2019 (COVID-19), we report a spatiotemporal description of SARS-CoV-2 infection and replication through the brain. SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Nature neuroscience - 26(2023), 2 vom: 09. Feb., Seite 226-238 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Villadiego, Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 09.02.2023 Date Revised 09.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41593-022-01242-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351353232 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351353232 | ||
| 003 | DE-627 | ||
| 005 | 20231226051149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41593-022-01242-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351353232 | ||
| 035 | |a (NLM)36624276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Villadiego, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2023 | ||
| 500 | |a Date Revised 09.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe coronavirus disease 2019 (COVID-19), we report a spatiotemporal description of SARS-CoV-2 infection and replication through the brain. SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a García-Arriaza, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Lorca, Reposo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Swinburn, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello-Rivera, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Rosales-Nieves, Alicia E |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez-Vergara, María I |e verfasserin |4 aut | |
| 700 | 1 | |a Cala-Fernández, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a García-Roldán, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a López-Ogáyar, Juan L |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Astorgano, David |e verfasserin |4 aut | |
| 700 | 1 | |a Albericio, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Cabello, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Mariano |e verfasserin |4 aut | |
| 700 | 1 | |a López-Barneo, José |e verfasserin |4 aut | |
| 700 | 1 | |a Toledo-Aral, Juan José |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature neuroscience |d 1998 |g 26(2023), 2 vom: 09. Feb., Seite 226-238 |w (DE-627)NLM09747679X |x 1546-1726 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:2 |g day:09 |g month:02 |g pages:226-238 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41593-022-01242-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 2 |b 09 |c 02 |h 226-238 | ||